WASHINGTON, Nov. 2 /PRNewswire-FirstCall/ -- Novo Nordisk today announced the appointment of Christopher Porter as director of government affairs in the United States. Prior to joining Novo Nordisk, Porter was the original co-staff director of the Congressional Diabetes Caucus. He also served as legislative director and chief of staff for three different members of the House.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020404/NVOLOGO )
“Christopher brings more than 15 years’ experience on Capitol Hill and in the lobbying community, and he will help strengthen our efforts to keep diabetes on the forefront of the national healthcare agenda,” said Michael Mawby, chief government affairs officer.
As government affairs director, Porter will lead all of Novo Nordisk’s federal lobbying activities in their recently opened Washington, D.C. offices.
“I am honored to join Novo Nordisk and assist in advancing the company’s commitment to defeat diabetes,” said Porter. “I look forward to supporting Novo Nordisk’s dedication in changing diabetes through the cultivation of relationships with key government leaders and agencies.”
Prior to joining Novo Nordisk, Porter spent five years with YourCongress, Inc., a company he founded in 2000, where he led its strategic consulting division and specialized in health care and appropriations. Porter has extensive experience in diabetes-related legislation, Medicare, Medicaid, and U.S. Food and Drug Administration issues. Most recently, he secured a major victory as a consultant/lobbyist for the American Diabetes Association in this summer’s SAFETEA-LU bill.
Graduating Cum Laude from The American University, Porter holds bachelor’s degrees in Political Science and Law and Society. A Presidential Scholar, he received University honors with Distinction.
Novo Nordisk is a healthcare company with an 80-year history of innovation and achievement in diabetes care. With the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems, Novo Nordisk is a world leader in diabetes care. In the United States, Novo Nordisk’s ambition is Changing Diabetes. Working as a catalyst to improve diabetes prevention and treatment, the company strives to be the preferred partner for employees, patients, healthcare providers, and others in the healthcare system who share its vision to defeat diabetes. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk’s business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs approximately 21,200 full-time employees in 78 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For global information, visit http://www.novonordisk.com; for United States information, visit http://www.novonordisk-us.com.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020404/NVOLOGOPRN Photo Desk photodesk@prnewswire.comNovo Nordisk Inc.
CONTACT: Media - Susan Jackson, +1-609-919-7776, or Investors - MadsVeggerby Lausten, +1-609-919-7937, both of Novo Nordisk
